Suscribirse

Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice - 19/04/17

Doi : 10.1016/j.jaci.2016.06.058 
Caitlin M. Gillis, BSci a, b, c, , Friederike Jönsson, PhD a, b, David A. Mancardi, PhD a, b, Naxin Tu, PhD e, Héloïse Beutier, PharmD a, b, c, Nico Van Rooijen, PhD d, Lynn E. Macdonald, PhD e, Andrew J. Murphy, PhD e, Pierre Bruhns, PhD a, b,
a Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France 
b INSERM, U1222, Paris, France 
c Université Pierre et Marie Curie, Paris, France 
d Department of Molecular Cell Biology, VU Medical Center, Amsterdam, The Netherlands 
e Regeneron Pharmaceuticals, Tarrytown, NY 

Corresponding authors: Pierre Bruhns, PhD, and Caitlin M. Gillis, BSci, Unit of Antibodies in Therapy and Pathology, Department of Immunology, Institut Pasteur, 25 rue du Docteur Roux, 75015 Paris, France.Unit of Antibodies in Therapy and PathologyDepartment of ImmunologyInstitut Pasteur25 rue du Docteur RouxParis75015France

Abstract

Background

Anaphylaxis can proceed through distinct IgE- or IgG-dependent pathways, which have been investigated in various mouse models. We developed a novel mouse strain in which the human low-affinity IgG receptor locus, comprising both activating (hFcγRIIA, hFcγRIIIA, and hFcγRIIIB) and inhibitory (hFcγRIIB) hFcγR genes, has been inserted into the equivalent murine locus, corresponding to a locus swap.

Objective

We sought to determine the capabilities of hFcγRs to induce systemic anaphylaxis and identify the cell types and mediators involved.

Methods

hFcγR expression on mouse and human cells was compared to validate the model. Passive systemic anaphylaxis was induced by injection of heat-aggregated human intravenous immunoglobulin and active systemic anaphylaxis after immunization and challenge. Anaphylaxis severity was evaluated based on hypothermia and mortality. The contribution of receptors, mediators, or cell types was assessed based on receptor blockade or depletion.

Results

The human-to-mouse low-affinity FcγR locus swap engendered hFcγRIIA/IIB/IIIA/IIIB expression in mice comparable with that seen in human subjects. Knock-in mice were susceptible to passive and active anaphylaxis, accompanied by downregulation of both activating and inhibitory hFcγR expression on specific myeloid cells. The contribution of hFcγRIIA was predominant. Depletion of neutrophils protected against hypothermia and mortality. Basophils contributed to a lesser extent. Anaphylaxis was inhibited by platelet-activating factor receptor or histamine receptor 1 blockade.

Conclusion

Low-affinity FcγR locus-switched mice represent an unprecedented model of cognate hFcγR expression. Importantly, IgG-related anaphylaxis proceeds within a native context of activating and inhibitory hFcγRs, indicating that, despite robust hFcγRIIB expression, activating signals can dominate to initiate a severe anaphylactic reaction.

El texto completo de este artículo está disponible en PDF.

Key words : Anaphylaxis, IgG, knock-in mouse model, basophil, neutrophil, monocyte, macrophage, human FcγR, platelet-activating factor, histamine

Abbreviations used : ASA, BAC, BAL, ES, HA, IVIG, NK, PAF, PAF-R, PSA, SSC


Esquema


 This work was supported by the European Research Council (ERC)–Seventh Frame-work Program (ERC-2013-CoG 616050). Additional support was provided by the Institut Pasteur and the Institut National de la Santé et de la Recherche Médicale (INSERM). C.M.G. was supported partly by a stipend from the Pasteur–Paris University (PPU) International PhD program and by the Institut Carnot Pasteur Maladies Infectieuses and partly by the Balsan company. F.J. is an employee of the Centre National de La Recherche Scientifique (CNRS). H.B. is supported by a fellowship from the University Pierre et Marie Curie.
 Disclosure of potential conflict of interest: N. Tu is an employee of Regeneron Pharmaceuticals. L. E. Macdonald is an employee of Regeneron Pharmaceuticals. A. J. Murphy is an employee of Regeneron Pharmaceuticals. P. Bruhns receives grant support from the European Research Committee. The rest of the authors declare that they have no relevant conflicts of interest.


© 2016  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 139 - N° 4

P. 1253 - avril 2017 Regresar al número
Artículo precedente Artículo precedente
  • Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults
  • Stacie M. Jones, Scott H. Sicherer, A. Wesley Burks, Donald Y.M. Leung, Robert W. Lindblad, Peter Dawson, Alice K. Henning, M. Cecilia Berin, David Chiang, Brian P. Vickery, Robbie D. Pesek, Christine B. Cho, Wendy F. Davidson, Marshall Plaut, Hugh A. Sampson, Robert A. Wood, Consortium of Food Allergy Research
| Artículo siguiente Artículo siguiente
  • Mast cells are associated with the onset and progression of celiac disease
  • Barbara Frossi, Claudio Tripodo, Carla Guarnotta, Antonio Carroccio, Marco De Carli, Stefano De Carli, Marco Marino, Antonino Calabrò, Carlo E. Pucillo

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.